ASH 2023 | Final analysis of the GIMEMA LAL2116 (D-ALBA) trial: dasatinib + blinatumomab in Ph+ B-ALL
Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, discusses the final follow-up of the GIMEMA LAL2116 (D-ALBA) trial (NCT02744768), a Phase II trial evaluating the safety and efficacy of dasatinib plus blinatumomab in adults with newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). Dr Chiaretti indicates that the final analysis, after 53 months, showed that this regimen induces durable disease-free survival (DFS) responses in patients with Ph+ B-ALL, as well as highlighting the outcomes of patients who went on to receive an allogeneic stem cell transplant (alloSCT). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Incyte: Membership on an entity’s Board of Directors or advisory committees; Abbvie: Membership on an entity’s Board of Directors or advisory committees; Gilead: Membership on an entity’s Board of Directors or advisory committees; Pfizer: Membership on an entity’s Board of Directors or advisory committees; Amgen: Membership on an entity’s Board of Directors or advisory committees.
